ALEC vs. TSHA, VALN, NK, EDIT, CCCC, SLDB, TRML, NVAX, REPL, and OCGN
Should you be buying Alector stock or one of its competitors? The main competitors of Alector include Taysha Gene Therapies (TSHA), Valneva (VALN), NantKwest (NK), Editas Medicine (EDIT), C4 Therapeutics (CCCC), Solid Biosciences (SLDB), Tourmaline Bio (TRML), Novavax (NVAX), Replimune Group (REPL), and Ocugen (OCGN). These companies are all part of the "medical" sector.
Taysha Gene Therapies (NASDAQ:TSHA) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.
Alector received 64 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 72.07% of users gave Taysha Gene Therapies an outperform vote while only 60.25% of users gave Alector an outperform vote.
Taysha Gene Therapies has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
In the previous week, Taysha Gene Therapies had 7 more articles in the media than Alector. MarketBeat recorded 9 mentions for Taysha Gene Therapies and 2 mentions for Alector. Alector's average media sentiment score of 0.59 beat Taysha Gene Therapies' score of 0.44 indicating that Taysha Gene Therapies is being referred to more favorably in the media.
77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 2.3% of Taysha Gene Therapies shares are held by insiders. Comparatively, 14.0% of Alector shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Taysha Gene Therapies has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
Alector has a net margin of -134.34% compared to Alector's net margin of -722.06%. Alector's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.
Taysha Gene Therapies presently has a consensus target price of $6.57, indicating a potential upside of 128.97%. Alector has a consensus target price of $14.50, indicating a potential upside of 140.86%. Given Taysha Gene Therapies' higher possible upside, analysts clearly believe Alector is more favorable than Taysha Gene Therapies.
Summary
Taysha Gene Therapies beats Alector on 10 of the 18 factors compared between the two stocks.
Get Alector News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools